MacroGenics Amends Proxy to Correct Equity Plan Share Count, Proposing 1.25M New Shares
MGNX has more than doubled off its 52-week low of $1.185.
Summary
MacroGenics filed an amended proxy statement to correct a clerical error, now seeking shareholder approval to add 1.25 million shares to its 2023 Equity Incentive Plan, which would result in a total of 3.74 million shares available for future grants.
Key Events · Corporate Governance and Compliance · MGNX
-
Equity Plan Amendment Proposed
The company is proposing to increase its 2023 Equity Incentive Plan by an additional 1,250,000 shares, subject to shareholder approval at the upcoming Annual Meeting.
-
Correction of Clerical Error
This filing amends a definitive proxy statement from April 8, 2026, to correct an inadvertent clerical error in the disclosure of the total number of shares available for grant under the plan.
-
Significant Potential Dilution
If approved, the total shares available for grant under the plan would be approximately 3,744,325, representing about 5.89% of current outstanding shares. The newly requested shares alone represent approximately 1.96% of outstanding shares.
-
Talent Retention Justification
MacroGenics emphasizes that the additional equity awards are vital for attracting, motivating, and retaining qualified employees, non-employee directors, and consultants in the highly competitive biopharmaceutical industry.
Analysis · MGNX · Life Sciences
This DEFA14A filing amends a previous proxy statement to correct a clerical error regarding the proposed increase in the 2023 Equity Incentive Plan. The company is seeking shareholder approval for an additional 1,250,000 shares, which, if approved, would bring the total shares available for grant to approximately 3,744,325. This represents a notable potential dilution for existing shareholders, though the company states it is crucial for attracting and retaining talent in a competitive biopharmaceutical market. Investors should review the updated share count ahead of the May 19, 2026 Annual Meeting.
At the time of this filing, MGNX was trading at $3.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $217.4M. The 52-week trading range was $1.19 to $3.88. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.